SOP Guide for Pharma

Biosimilars: SOP for Stable Cell Line Development – V 2.0

Auditor


Biosimilars: SOP for Stable Cell Line Development – V 2.0


Standard Operating Procedure for Stable Cell Line Development in Biosimilar R&D

Department Biosimilars
SOP No. SOP/BS/015/2025
Supersedes SOP/BS/015/2022
Page No. Page 1 of 14
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standardized procedure for the development of stable mammalian cell lines expressing biosimilar therapeutic proteins. This includes transfection, clone selection, expansion, and characterization steps.

2. Scope

This SOP applies to biosimilar R&D personnel involved in generating and validating stable expression cell lines for preclinical and commercial biosimilar development.

3. Responsibilities

See also  Biosimilars: SOP for ELISA-Based Screening of Clones - V 2.0

4. Accountability

The Head of Cell Line Development is accountable for ensuring regulatory-compliant execution and traceability of stable cell line generation activities.

5. Procedure

5.1 Preparation for Transfection

  1. Maintain parental cell lines (e.g., CHO, HEK293) in exponential growth phase.
  2. Confirm cell viability (>90%) and absence of contamination.
  3. Prepare transfection-grade plasmid DNA encoding the biosimilar gene of interest and selection marker.

5.2 Transfection

  1. Transfect cells using electroporation or lipid-based reagent per protocol.
  2. Plate transfected cells in T-75 or 6-well plates in antibiotic-free medium for 24–48 hours.

5.3 Antibiotic Selection

  1. Determine kill curve for antibiotic (e.g., G418, Hygromycin) prior to application.
  2. Add selection medium at predetermined lethal concentration and monitor for 10–14 days.
  3. Change medium every 3–4 days.

5.4 Clone Isolation

  1. Isolate single colonies using cloning rings or limiting dilution cloning.
  2. Expand clones to 24-well plates, then to 6-well plates and T-25 flasks.
  3. Maintain Clone Tracking Log (Annexure-1) throughout.
See also  Biosimilars: SOP for Agarose Gel Electrophoresis - V 2.0

5.5 Expression Screening

  1. Screen for expression using ELISA or Western blot.
  2. Select top-performing clones with high and stable protein expression.
  3. Document results in Expression Analysis Log (Annexure-2).

5.6 Clone Expansion and Characterization

  1. Expand selected clones to generate enough biomass for further testing.
  2. Confirm identity, gene copy number, productivity, and glycosylation profile.
  3. Document characterization in Stable Clone Profile Sheet (Annexure-3).

5.7 Master Cell Bank (MCB) Generation

  1. Freeze vials of confirmed stable clones under GMP-like conditions.
  2. Label each vial with Clone ID, batch no., and date.
  3. Store at -80°C and then transfer to liquid nitrogen storage.

6. Abbreviations

7. Documents

  1. Clone Tracking Log (Annexure-1)
  2. Expression Analysis Log (Annexure-2)
  3. Stable Clone Profile Sheet (Annexure-3)

See also  Biosimilars: SOP for Transient Transfection Methods - V 2.0

8. References

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Clone Tracking Log

Date Clone ID Plate Type Passage Operator
02/05/2025 CL-BS-015 24-well P2 Rajesh Kumar

Annexure-2: Expression Analysis Log

Clone ID Method Expression Level Remarks Date
CL-BS-015 ELISA 125 ng/mL High Expressor 03/05/2025

Annexure-3: Stable Clone Profile Sheet

Clone ID Gene Copy No. Glycan Profile MCB Created MCB Location
CL-BS-015 8 Comparable to Reference Yes CryoTank A2

Revision History:

Revision Date Revision No. Details Reason for Revision Approved By
04/05/2025 2.0 Updated MCB generation steps and added Annexure-3 Annual Review
Exit mobile version